Mohamed Sikkander Abdul Razak: A Single Stem Cell Generating 14 Million Tumor-Killing NK Cells
Mohamed Sikkander Abdul Razak, Professor at GKM College of Engineering Technology, shared a post on LinkedIn, adding:
“Recent studies have shown that a single stem cell can generate up to 14 million tumor-killing NK cells, which is a remarkable achievement in cancer immunotherapy.
This breakthrough could lead to more effective treatments for various types of cancer.
The research focuses on engineering early-stage stem cells from cord blood, which has shown promising results in producing large quantities of highly potent NK cells.
These cells can be equipped with CAR (Chimeric Antigen Receptor) technology to target specific cancer cells, offering new hope for cancer patients.
Recent research has shown a significant increase in cancer-fighting NK cells, with an 80% increase in their activities.
This breakthrough is attributed to the use of stem cells from cord blood, which can generate large quantities of highly potent NK cells.
These cells can be engineered with CAR (Chimeric Antigen Receptor) technology to target specific cancer cells, offering new hope for cancer patients.
NK cells play a crucial role in cancer immunotherapy, recognizing and killing tumor cells without prior sensitization.
They exert their effects through various mechanisms, including releasing perforin, granzyme, and secreting cytokines like interferon-γ (IFN-γ).
Key Mechanisms of NK Cell Therapy:
- Direct Killing: NK cells release cytotoxic granules to induce tumor cell death.
- Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC): NK cells mediate ADCC through FcγRIIIa (CD16).
- Cytokine Secretion: NK cells secrete cytokines like IFN-γ to modulate the immune response.
- Clinical Applications:
- Hematologic Malignancies: NK cell therapies have shown response rates ranging from 40% to 80%.
- Solid Tumors: Ongoing research explores NK cell therapy’s potential in treating solid tumors.
Recent advances in CAR-NK cell therapy are revolutionizing cancer treatment, offering safer and more effective options.
This innovative approach harnesses natural killer cells’ innate cytotoxic capabilities, combined with precise genetic engineering, to target cancer cells.
Key Benefits:
- Reduced toxicity: CAR-NK cells exhibit minimal cytokine release syndrome and neurotoxicity compared to CAR-T cells.
- Broad applicability: Effective against hematological malignancies and solid tumors.
- Off-the-shelf potential: Scalable production and cryopreservation enable rapid treatment.
Ongoing Research:
- Optimizing CAR design and combination therapies.
- Enhancing in-vivo persistence and overcoming immunosuppressive tumor microenvironments.
- Exploring applications in autoimmune diseases and infectious diseases.
Notable breakthroughs include:
- Menin inhibitors: Show promise in treating acute myeloid leukemia (AML) and pancreatic cancer.
- Protein degraders: Novel therapies targeting cancer-driving proteins.
- Diet and exercise: Lifestyle interventions improving cancer treatment outcomes.”
Stay updated with Hemostasis Today.
-
Apr 14, 2026, 09:32Kalyan Roy: Swirling as a Simple Indicator of Platelet Quality
-
Apr 14, 2026, 09:26Kausik Ray: How Physicians and Patients Perceive Risk in Lipid Modification Therapy
-
Apr 14, 2026, 09:14Hossam Qassem: When To Start Anticoagulation After Cerebral Aneurysm Clipping
-
Apr 14, 2026, 09:09Kevin Land: Near Elimination of Vaso-Occlusive Crises in Sickle Cell Disease
-
Apr 14, 2026, 07:58Anton Ilich։ A New Test for Rapid Detection of Fibrinolysis in Postpartum Hemorrhage
-
Apr 13, 2026, 17:41Peter Zdziarski: Glanzmann’s Research Foundation Listed as GT Patient Organization on NORD
-
Apr 13, 2026, 17:39Nathan Connell: Why Prophylaxis in vWD Has Historically Lagged Behind Established Practice in Hemophilia
-
Apr 13, 2026, 17:38Tareq Abadl: A Blood Transfusion Can Cause a Delayed Platelet Crash
-
Apr 13, 2026, 13:33Tetsumei Urano: Join for the ISTH Educational Programs at APSTH 2026 in Japan